synthorx Logo (WIPO, 10.07.2020)
WIPOSchützen Sie diese Marke vor Nachahmern!
Mit unserer Markenüberwachung werden Sie automatisch per E-Mail über Nachahmer und Trittbrettfahrer benachrichtigt.
Die Internationale Marke synthorx wurde als Bildmarke am 10.07.2020 bei der Weltorganisation für geistiges Eigentum angemeldet.
Logodesign (Wiener Klassifikation)
#Armillarsphären, Planetarien, astronomische Umlaufbahnen, Atommodelle, molekulare Modelle #Buchstaben oder Ziffern, die einen Menschen, ein Tier, eine Pflanze, einen Himmelskörper, ein Naturphänomen oder einen Gegenstand darstellen #Atomare Modelle, molekulare Modelle, Darstellungen von menschlichen, tierischen oder pflanzlichen Zellen #Buchstaben oder Ziffern, die einen Menschen oder einen Teil des menschlichen Körpers, ein Tier oder einen Teil des Körpers eines Tieres, eine Pflanze, einen Himmelskörper, ein Naturphänomen oder einen Gegenstand darstellen
| Markenform | Bildmarke |
| Aktenzeichen | 1562572 |
| Länder | 
|
| Basismarke |
Nr. 88505851,
09. Juli 2019
|
| Anmeldedatum | 10. Juli 2020 |
| Ablaufdatum | 10. Juli 2030 |
Markeninhaber
11099 North Torrey Pines Road, Suite 190
La Jolla CA 92037
US
La Jolla CA 92037
US
Markenvertreter
31 rue de Fleurus
F-75006 Paris
FR
Waren und Dienstleistungen
05
Protein therapeutics expressed, prepared or manufactured
using a semi-synthetic organism, namely, pharmaceutical
preparations for use in immunology, oncology including
immuno-oncology, cardiovascular and metabolic diseases and
infectious diseases; protein therapeutics expressed,
prepared or manufactured using a semi-synthetic organism,
namely, proteins designed to deliver highly targeted
therapeutic modulation for patients suffering from a variety
of diseases, including cancer, autoimmune and inflammatory
diseases including transplantation and delayed-type
hypersensitivity, respiratory diseases, gastrointestinal
diseases, cardiovascular and metabolic diseases, pathogen
infections, musculoskeletal diseases, ophthalmologic and
dermatologic diseases, genitourinary diseases, degenerative
diseases and orphan diseases; protein therapeutics namely,
pharmaceutical preparations for use in immunology including
rheumatology, oncology including immuno-oncology,
pulmonology, gastroenterology, endocrinology, dermatology,
urology, gynecology including fertility, infectiology
including virology, ophthalmology, hepatology, neurology and
geriatrics; protein therapeutics, namely, proteins designed
to deliver highly targeted therapeutic modulation for
patients suffering from a variety of diseases, including
cancer and autoimmune disorders, cytokines, interferons,
tumor cell targeting and cytolytic agents, tolerogenic and
antiallergic factors, growth and differentiation factors,
hormones, replacement enzymes, coagulation factors, lipid
binding proteins, protein factors for manufacturing of
adoptive cell therapy products, anti-infectives, pain
killers, and tissue repair factors; modified protein to be
used in connection with a variety of therapeutic areas,
namely protein arrays for medical diagnostic purposes;
pharmaceutical preparations, namely, synthetic proteins for
use in immunology including rheumatology, oncology including
immuno-oncology, pulmonology, gastroenterology,
endocrinology, dermatology, urology, gynecology including
fertility, infectiology including virology, ophthalmology,
hepatology, neurology and geriatrics
42
Medical research; scientific research in the field of DNA;
pharmaceutical research and development; laboratory research
services in the field of pharmaceuticals; pharmaceutical
research in the field of protein therapeutics;
pharmaceutical research in the fields of immunology
including rheumatology, oncology including immuno-oncology,
pulmonology, gastroenterology, endocrinology, dermatology,
urology, gynecology including fertility, infectiology
including virology, ophthalmology, hepatology, neurology,
geriatrics, genetics and phenomics, pathology and forensics,
proteomics and veterinary medicine and diagnostics;
providing medical and scientific research information in the
field of pharmaceuticals and clinical trials; pharmaceutical
research using a semi-synthetic organism for use in drug
development; pharmaceutical research, namely, research
relating to synthetic proteins incorporating one or more
non-natural amino acids for improving pharmacological
properties; pharmaceutical research, namely, research
relating to synthetic proteins for use in connection with a
wide variety of therapeutic agents
Die Bezeichnungen wurden automatisch übersetzt. Übersetzung anzeigen
Markenhistorie
| Datum | Belegnummer | Bereich | Eintrag |
|---|---|---|---|
| 19. Mai 2022 | 2022/23 Gaz | MX | Ablehnung |
| 05. Mai 2022 | 2022/18 Gaz | TH | Ablehnung |
| 30. März 2022 | 2022/14 Gaz | CA | Ablehnung |
| 10. März 2022 | 2022/11 Gaz | JP | RAW: Rule 18ter(2)(ii) GP following a provisional refusal |
| 07. Dezember 2021 | 2021/49 Gaz | KR | Ablehnung |
| 17. November 2021 | 2021/46 Gaz | VN | Ablehnung |
| 28. Oktober 2021 | 2021/43 Gaz | JP | Ablehnung |
| 27. Oktober 2021 | 2021/43 Gaz | CH | Ablehnung |
| 23. Oktober 2021 | 2021/43 Gaz | ID | Ablehnung |
| 21. Oktober 2021 | 2021/42 Gaz | OA | Ablehnung |
| 14. Oktober 2021 | 2021/41 Gaz | NO | Ablehnung |
| 24. August 2021 | 2021/34 Gaz | BR | Ablehnung |
| 07. Juni 2021 | 2021/25 Gaz | DZ | Ablehnung |
| 15. April 2021 | 2021/15 Gaz | EM | Ablehnung |
| 05. April 2021 | 2021/14 Gaz | GB | Ablehnung |
| 23. März 2021 | 2021/12 Gaz | CN | Ablehnung |
| 14. März 2021 | 2021/11 Gaz | PH | Ablehnung |
| 03. März 2021 | 2021/9 Gaz | AU | Ablehnung |
| 01. März 2021 | 2021/9 Gaz | RU | Ablehnung |
| 10. Juli 2020 | 2020/46 Gaz | US | Eintragung |
ID: 141562572